| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) | In curs de recrutare | Bucharest, Romania, 10825, Contact: Contact 1-888-EXELIXIS (888-393-5494) Bucharest, Romania, 11863, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, Romania, 400058, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, RomaniaTimisoara, Romania, 300723 |
| 2 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy | In curs de recrutare | Exelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385Exelixis Clinical Site #142, Timişoara, Timis, Romania, 300166Exelixis Clinical Site #146, Bucuresti, Romania, 011863 |
| 3 | A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Activ, inca nu se recruteaza | Facility #1, Cluj-Napoca, Cluj, Romania, 400058Facility #1, Bucharest, Romania, 11863 |
| 4 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | Activ, inca nu se recruteaza | Investigational Site Number 1801, Bucharest, Romania |
(Visited 27 times, 1 visits today)